Astrazeneca Plc ADR (AZN)
$76.80
0.19 (0.25%)
AZN Stock Quote Delayed 30 Minutes
Hottest Healthcare Stocks Now – GILD THC HCA CYH
Healthcare stocks declined broadly on Wall Street so far on Wednesday, with the sector seeing an overall decline of 0.7%. NASDAQ:GILD, NYSE:THC, NYSE:HCA, NYSE:CYH, NYSE:AZN, NASDAQ:CBST, NYSE:UHS, NASDAQ:XLRN, NASDAQ:LPNT, NYSE:CHE, NASDAQ:ISRG, NASDAQ:LGND, NYSE:PBYI, NASDAQ:ALNY, NASDAQ:AMGN, NYSE:BCR, NASDAQ:ISIS, NASDAQ:SRPT, NASDAQ:INCY, NYSE:MSA
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
2.38M
Day's Range
$76.49 - $77.01
52-Week Range
$60.47 - $80.86
Dividend & Yield
$0.93 (1.21%)
AZN Stock Predictions, Articles, and Astrazeneca Plc ADR News
5 Pharma Stocks to Buy for Big Dividends
Drugmakers aren't known for big dividends, but the pharmaceutical industry can actually offer something for income investors.
It May Be Time to Trim Away at Your Portfolio
The stock market is doing well for October, but its may be time to look through your portfolio in order to trim away some of the upcoming losers
Flu Season Is Coming — And These Companies Are Ready
Flu season is slowly getting started -- bad news for us, but welcome news for companies that benefit from flu sufferers' ills. Here's a look at some of them.
3 Pharma Stocks Just Running in Place
Gobs of free cash flow doesn't mean a company is worth buying. Some companies, especially pharmaceuticals, just use cash to run in place.
3 Healthcare Stocks With Healthy Dividends
Protect yourself from the headwinds facing healthcare stocks by snatching up names that offer -- and are likely to keep offering -- big-time dividends.
3 Ways to Play the M&A Wave
Want to get in on Wall Street's wheeling and dealing without taking on the risk of gambling on the next buyout target? Try these three options instead.
Is M&A Mania Poised to Keep Fanning the Market’s Flames?
America's renewed push of merger & acquisition action has the potential to drive market optimism and help buoy stocks -- but which stocks, and for how long?
AstraZeneca to Purchase Omthera
AstraZeneca will purchase Omertha, a make of fish-oil based pharmaceuticals as it continues to bolster its cardiovascular product lineup
Should I Buy Pfizer? 3 Pros, 3 Cons
Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore.
3 New Dividend Funds Let You ‘Pick Your Risk’
FlexShares' new trio of "Quality" dividend ETFs allows you to "pick your risk profile," but still doesn't seem to add much spice to the dividend-fund world.
India Drops Patent Bomb on Novartis
India's ruling on a Novartis patent draws a clear line of favor between generic drug companies and Big Pharma.
Flu’s Pain Is All Gain for These Companies
As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers.
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
S&P 500 Ends Its Streak — Thursday’s IP Market Recap
The markets ended in the red for the day in the wake of Boehner's fiscal cliff remarks, and in the face of strong retail sales and a sharp slide in jobless claims.
Big Pharma: 2012-13’s Flu Vaccine Field
Here's a look at the various big pharma stocks that could see a bump from an early start to this year's flu season.
Biotech Movers: A Tough Week All Around
Amarin Corp. slides on dashed buyout hopes, while Sarepta, Galena and others also faced serious setbacks.
6 Pharmaceutical Stocks to Sell Now
For the current week, the overall ratings of six Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
6 Pharmaceutical Stocks to Sell Now
For the current week, the overall ratings of six Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Novartis Flu Vaccine Ban: Who Wins?
Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why.
